4//SEC Filing
Provost Miriam 4
Accession 0000950170-23-046432
CIK 0001756262other
Filed
Sep 4, 8:00 PM ET
Accepted
Sep 5, 4:36 PM ET
Size
12.5 KB
Accession
0000950170-23-046432
Insider Transaction Report
Form 4
Provost Miriam
VP of US Regulatory & FDA Rel.
Transactions
- Exercise/Conversion
Common Stock
2023-08-31$3.22/sh+1,785$5,748→ 22,624 total - Exercise/Conversion
Common Stock
2023-08-31$38.46/sh+3,695$142,110→ 26,319 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-08-31−1,785→ 16,496 totalExercise: $3.22Exp: 2028-04-05→ Common Stock (1,785 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2023-08-31−3,695→ 11,410 totalExercise: $38.46Exp: 2031-02-24→ Common Stock (3,695 underlying) - Sale
Common Stock
2023-08-31$66.52/sh−2,708$180,136→ 23,611 total
Footnotes (5)
- [F1]The exercise followed the sell-to-cover process, whereby a portion of the shares acquired through the exercise were sold in the open market, with the proceeds used to fund the aggregate exercise price of the options.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $66.40 to $66.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]Includes 5,685 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- [F4]The option is fully vested.
- [F5]The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 24, 2021.
Documents
Issuer
TransMedics Group, Inc.
CIK 0001756262
Entity typeother
Related Parties
1- filerCIK 0001773663
Filing Metadata
- Form type
- 4
- Filed
- Sep 4, 8:00 PM ET
- Accepted
- Sep 5, 4:36 PM ET
- Size
- 12.5 KB